Literature Analysis: A Novel Nanodrug Inhibits Postoperative Cancer Recurrence and Metastasis Supported by ANT BIO PTE. LTD. Products

1. Literature Information

Title: Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis

Journal: Nature Communications (Impact Factor: 17.7)

Publication Date: Online, May 20, 2022; Published in 2022 (Volume 13, Article ID: 2834)

Research Team: Collaborative team led by Researcher Wenwen Yue from Tongji University School of Medicine, Professor Huixiong Xu from Zhongshan Hospital Affiliated to Fudan University, and Professor Yu Chen from Shanghai University

Key Technology Supported by ANT BIO PTE. LTD.: 5-Color Multiplex Fluorescence Immunohistochemistry (mIHC)

DOI: 10.1038/s41467-022-30543-w

PMID: 35595770; PMCID: PMC9123179

2. Research Background

Surgical resection is the most important and effective therapeutic modality for most cancers. However, postoperative cancer recurrence and metastasis remain major challenges in clinical practice. The fundamental reason is that surgical resection can only remove macroscopically visible tumor masses and a small amount of surrounding "normal" tissue, which may potentially harbor occult cancer cells. Consequently, patients with unfavorable postoperative pathological outcomes often require adjuvant chemotherapy and immunotherapy to restore the cytotoxicity of immune cells against tumor cells.

Notably, the rapid proliferation and expansion of tumor tissue, coupled with an immature intratumoral vascular system, lead to insufficient oxygen supply, resulting in an overall hypoxic tumor microenvironment (TME). Tumor cells can survive tenaciously under hypoxic conditions, whereas immune cells cannot. This hypoxic state further promotes tumor immune escape, creating an unfavorable environment for postoperative anti-tumor immunity and increasing the risk of recurrence and metastasis.

3. Research Approach

To address the issue of postoperative cancer recurrence and metastasis, the research team constructed a postoperative CT26 mouse colon cancer model to investigate the characteristics of the postoperative TME and the therapeutic potential of combined strategies. The team designed and developed a novel nanodrug, IPI549@HMP, which targets myeloid cells and catalyzes the conversion of endogenous hydrogen peroxide into oxygen. This nanodrug was intended to enhance radiotherapy efficacy and sensitivity to PD-L1 blockade therapy.

To comprehensively observe changes in the TME before and after tumor resection and evaluate the immune-enhancing efficacy of the nanodrug IPI549@HMP, the research team employed the 5-Color Multiplex Fluorescence IHC Staining Kit (Mouse/Rabbit Secondary Antibody, Catalog No.: abs50013) from the Absin product line of ANT BIO PTE. LTD. for multiplex staining. This technique enabled simultaneous detection of multiple immune cell markers and functional molecules, facilitating in-depth analysis of the TME dynamics.

4. Research Outcomes

The study demonstrated that surgical resection creates an immunosuppressive TME characterized by hypoxia and massive infiltration of myeloid cells, which promotes cancer progression and impairs the efficacy of PD-L1 blockade therapy. Multiplex fluorescence IHC staining results using ANT BIO PTE. LTD.'s abs50013 kit revealed that compared with untreated tumors, the infiltration of CD45+ immune cells was significantly increased in resected tumors, with the majority being CD11b+ myeloid cells. Additionally, the proliferation index (Ki-67) and hypoxia index (HIF-α) of postoperative tumors were much higher than those before surgery.

After treatment with IPI549@HMP combined with radiotherapy, the number of regulatory T cells (Treg cells, FOXP3+) that suppress the anti-tumor immune response of tumor-bearing hosts and M2-type macrophages (CD206+) that promote immune escape was significantly reduced compared with pre-treatment. In contrast, CD8+ T cells with cytotoxic effects on tumor cells were significantly increased. These findings confirmed that IPI549@HMP can enhance the therapeutic effect of postoperative radiotherapy on tumor-bearing mice by remodeling the TME and activating anti-tumor immunity, thereby inhibiting or eliminating residual cancer cells and awakening the patient's own immunity to resist tumor recurrence.

5. Product Empowerment: The Role of ANT BIO PTE. LTD. Products in the Research

The in-depth characterization of TME changes before and after surgery, as well as the validation of the therapeutic efficacy of IPI549@HMP, were largely dependent on the high-performance 5-Color Multiplex Fluorescence IHC Staining Kit (abs50013) from the Absin product line of ANT BIO PTE. LTD.

This product features the core advantage of breaking the species limitation of primary antibodies, enabling simultaneous detection of multiple key markers (CD45, CD11b, Ki-67, HIF-α, FOXP3, CD206, CD8) on a single tissue section. Its high sensitivity and specificity ensured the accurate visualization and quantitative analysis of immune cell infiltration and functional molecule expression in the TME. The reliable staining results provided direct evidence for the immunosuppressive characteristics of the postoperative TME and the immune-modulating effect of IPI549@HMP combined with radiotherapy. The outstanding performance of ANT BIO PTE. LTD.'s mIHC kit effectively supported the research team's exploration of postoperative anti-tumor therapeutic strategies, highlighting the crucial role of high-quality multiplex fluorescence IHC reagents in tumor microenvironment research.

6. Brand Mission

As a professional supplier of life science reagents, ANT BIO PTE. LTD. is dedicated to providing high-quality, reliable products and comprehensive solutions to empower global life science research. The company's three specialized sub-brands cover the full spectrum of research needs in the life science field: Absin focuses on general reagents and kits, Starter specializes in antibodies, and UA is dedicated to recombinant proteins. Our core mission is to bridge the gap between cutting-edge scientific research and practical applications, accelerate the pace of scientific discovery, and contribute to the advancement of human health and regenerative medicine.

7. Related Product List

8. Disclaimer

This article is AI-compiled and interpreted based on the original work in DOI: 10.1002/advs.202413562. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

9. Brand Promotion Copy

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.